Natco share price

• Stock Returns vs Nifty Midcap 100 Stock gave a 3 year return of 2.31% as compared to Nifty Midcap 100 which gave a return of 142.42%. (as of last trading session) • Stock Returns vs Nifty Pharma Stock generated 2.31% return as compared to Nifty Pharma which gave investors 30.16% return over 3 year time period. (as of last trading session) NAME P/E (x) P/B (x) ROE % ROCE % ROA % Rev CAGR [3Yr] OPM NPM Basic EPS Current Ratio Total Debt/ Equity (x) Total Debt/ CFO (x) 16.31 2.39 14.67 17.61 12.64 11.49 32.37 26.42 39.18 4.39 0.03 0.00 21.27 2.09 9.81 13.89 8.89 11.59 30.85 21.54 47.44 9.46 0.00 0.00 29.55 7.00 23.70 31.27 20.92 17.44 42.16 30.68 16.16 6.37 0.04 0.00 35.11 2.75 7.82 9.58 5.53 6.97 7.70 6.59 17.40 1.78 0.15 0.00 -58.97 1.62 -2.75 1.65 -1.28 0.00 2.49 -3.40 -1.57 1.26 0.81 0.00 Add More • Stock Returns vs Nifty Midcap 100 Stock gave a 3 year return of 2.31% as compared to Nifty Midcap 100 which gave a return of 142.42%. (as of last trading session) • Stock Returns vs Nifty Pharma Stock generated 2.31% return as compared to Nifty Pharma which gave investors 30.16% return over 3 year time period. (as of last trading session) Meeting Date Announced on Purpose Details May 29, 2023 May 19, 2023 Board Meeting Audited Results Mar 08, 2023 Mar 02, 2023 Board Meeting Buy Back of shares Feb 09, 2023 Jan 31, 2023 Board Meeting Quarterly Results & Interim Dividend Nov 10, 2022 Oct 31, 2022 Board Meeting Quarterly Results & 2nd Interim Dividend Aug 09, 2022 Aug 01, 2022 B...

Natco said, the increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil. Our Crop Health Division started off well with strong growth potential in the ensuing years. Read here: For the full year FY23, Natco posted a consolidated total revenue of ₹2811.7 crore as against ₹2043.8 crore for the last year, reflecting 37.6% growth. The net profit for the period, on a consolidated basis, was ₹715.3 crore, as against ₹170 crore last year. Natco plans to incorporate a subsidiary company in Colombia with an investment up to an amount not exceeding $ 1,00,000. Also, the company is set to acquire a 100% stake in the UK-based company, Zista Pharma. Read here: ₹27 cr, revenue up 70% YoY Post the acquisition, Zista will become a wholly-owned subsidiary of Natco Pharma. After the Q4 results, Natco's share price closed at ₹635.10 apiece up by 0.91% on BSE. The stock has touched an intraday high of ₹659.35 crore due to healthy quarterly earnings.

Natco Pharma Ltd. Quick Overview Natco Pharma Limited is an India-based vertically integrated, research and development (R&D)-focused pharmaceutical company. The Company is engaged in the development, manufacture and commercialization of complex pharmaceuticals catering to niche therapeutic areas. The Company deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The Company operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.

Natco has, over the years, developed a knack for manufacturing complex generic products with few competitors, especially for the US market. • India formulations mainly comprise oncology products (38 brands). For the US, it follows partnership products for risky launches and acquired Dash Pharma for front-end presence. It has six FDF, two API manufacturing facilities and two crop health sciences units • Maiden entry into crop protection was via launch of pheromone product, Natmate PBW for controlling pink bollworm in cotton • FY22 revenue break-up - domestic business: 25%, international business: 62% (mainly from the US), APIs: 13% Revenues were buoyed by gains from gRevlimid, in the export formulation segment while Natco booked inventory write-off for Covid products of ₹ 232 crore and provisioning towards estimated credit loss of ₹ 46 crore. • Sales were up 80% YoY to ₹ 597 crore • Adjusted EBITDA for one-offs was at ₹ 259 crore, with margins at 43% • Booked loss of ₹ 50 crore vs. profit of ₹ 53 crore in Q4FY21 Description • NATCO is an Indian pharmaceutical company that manufactures and markets various pharmaceutical drugs, healthcare products, and chemical formulations. The company also provides chemical manufacturing services on a contract basis. NATCO is headquartered in Hyderabad. In addition to India, NATCO has operations in Canada, Australia, the Philippines, Brazil, and other countries. The company is known as a major producer of cancer-related medicines and drugs ...

Natco Pharma Limited is an India-based vertically integrated, research and development (R&D)-focused pharmaceutical company. The Company is engaged in the business of pharmaceuticals, which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The Company deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The Company operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.;